At what enterprise value was IMAPOLE acquired in 2022?

During the acquisition of IMAPOLE by EURAZEO in 2022, the company was valued at an estimated revenue multiple of 5x - 12x. The transaction's Enterprise Value is estimated to be in the range of 100M - 350M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of IMAPOLE when it was acquired by EURAZEO?

The estimated EV/EBITDA multiple for IMAPOLE is in the range of 15x - 25x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was IMAPOLE acquired by EURAZEO?

IMAPOLE was acquired by EURAZEO in 2022.

What was the revenue of IMAPOLE at the time of the deal?

The revenue of IMAPOLE at the time of the deal is estimated to be in the range of 5M - 25M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of IMAPOLE during the acquisition?

IMAPOLE's EBITDA is estimated to be in the range of 5M - 25M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the IMAPOLE acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the IMAPOLE deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://fr.newsroom.eurazeo.com/actualites/le-fonds-nov-sante-actions-non-cotees-investit-dans-imapole-69f34-7ed35.html

← DATABASE

Home Database Healthcare & PharmaIMAPOLE

09/2022

IMAPOLE acquired by EURAZEO

FRANCE Health Providers / Outpatient Care / Radiology EV 100M - 350M EUR

Context

Eurazeo has partnered with Bpifrance to complete a major investment of over EUR 50 million in Imapole. This investment marks a strategic turning point in the professionalization of regional medical imaging groups in France. The strategic rationale for this transaction centers on a "platform-build" play, merging the group’s practitioner-led operational depth with the sponsors' extensive expertise in healthcare scaling and digital transformation. This structural alignment provides the organization with the institutional capital and strategic hardware required to address the high demand for imaging capacity in under-served areas.

IMAPOLE, which reported an EBITDA margin of LOGIN in 2021, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Based in Lyon, ImaOne is a prominent medical imaging group. The organization is managed and owned by a group of associate radiologists, providing essential diagnostic services to the regional healthcare ecosystem. As an independent player in the medical imaging sector, the group focuses on maintaining high standards of clinical excellence while navigating the evolving regulatory landscape for medical practices in France. Its operational model relies on the expertise of its medical associates to deliver specialized imaging services, ranging from standard diagnostics to advanced medical screenings.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2021

2020

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
11/2022	RADNET	HEART & LUNG IMAGING	UNITED KINGDOM	Health Providers	RadNet, a US-based medical imaging specialist, has acquired a 75% majority stake in Heart & Lung Imaging Limited (HLH), a UK-based teleradiology network focused on detecting and diagnosing lung and cardiovascular diseases
10/2022	CBPE CAPITAL	VEINCENTRE	UNITED KINGDOM	Health Providers	CBPE Capital has completed a majority investment in Veincentre, acquiring the stake previously held by Palatine Private Equity alongside the company,s founders. This transaction marks a secondary LBO for the specialist clinic group, which saw significant growth under Palatine,s three-year ownership, including the expansion from 7 to 22 clinics
09/2022	ORADIANSE	REVEL	FRANCE	Health Providers	Oradianse, a leading group of radiologists, has acquired a radiology practice in Revel, located in the Haute-Garonne region near Toulouse. This move is part of the company's territorial development strategy, aimed at strengthening its presence in the Occitanie region and consolidating its national network of medical imaging centers
08/2022	FREEMAN SPOGLI	EVERVET PARTNERS	UNITED STATES	Health Providers	Freeman Spogli & Co. made a significant investment in EverVet Partners, partnering alongside existing investor Tailwind Capital while EverVet's founders and management retained meaningful equity stakes
07/2022	INFRAVIA CAPITAL	UNIVET	FRANCE	Health Providers	InfraVia Capital Partners acquired a minority stake in Univet from Platina Equity Solutions, which had been a partner since 2018. The transaction was structured as a combination of secondary share purchases and a primary capital increase, financed entirely through equity from InfraVia's EUR5 billion European Fund V
07/2022	ANDERA PARTNERS	GROUPE RESONANCE IMAGERIE	FRANCE	Health Providers	R�sonance Imagerie, a prominent French medical imaging group, has secured a major financing package from Andera MidCap, Ardian Private Debt, and Five Arrows Debt Partners. Established in 2011, the group currently operates a network of 15 centers across Paris, �le-de-France, and the Centre-Val-de-Loire region, managing 23 high-tech units including MRIs and scanners
07/2022	LATOUR CAPITAL	PHARMACIE LAFAYETTE - GROUPE HYGIE31	FRANCE	Health Providers	Latour Capital and Bpifrance acquired a majority stake in Hygie31, the holding company of Pharmacie Lafayette, from Five Arrows (Rothschild & Co). The deal aims to accelerate the group's development in France and Europe through organic growth and an ambitious buy-and-build strategy
06/2022	TRITON PARTNERS	ESPERI CARE	FINLAND	Health Providers	Triton Partners, via its Triton Smaller Mid Cap Fund II, acquired a majority stake in Esperi Care Oy from a consortium of its former creditors, including Danske Bank, SEB, and Ilmarinen, which remain as minority shareholders
06/2022	EURAZEO	SEVETYS	FRANCE	Health Providers	Eurazeo acquired a majority stake in Sevetys from Ardian, which had previously financed the group's initial rapid expansion. The transaction included a EUR250 million equity injection from Eurazeo to fuel a new phase of aggressive growth
06/2022	ARDIAN	SIMAGO	FRANCE	Health Providers	Ardian acquired a significant minority stake in Simago. The investment was designed to support the group's rapid "buy-and-build" strategy in a highly fragmented French market. Unlike traditional LBOs, the deal was structured to preserve the medical independence of the associate radiologists, who continue to hold the majority of the capital and voting rights alongside the founding management team

REFERENCES

Valuation range: EV 100M - 350M EUR

Revenue range: 5M - 25M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of IMAPOLE by EURAZEO are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Acquirer: eurazeo